Emergent Biosolutions (EBS) Gets a Buy Rating from Cantor Fitzgerald


In a report released yesterday, Brandon Folkes from Cantor Fitzgerald reiterated a Buy rating on Emergent Biosolutions (EBS), with a price target of $75. The company’s shares closed yesterday at $63.72.

Folkes noted:

“. Post 4Q18, we are reiterating our Overweight rating and our 12-month price target of $75. EBS continues to be the leader in the biodefense field, and the acquisition of Adapt and PaxVax leverage the company’s historical expertise, while further diversifying revenue away from BioThrax. We continue to believe the company’s business is a lot more durable than the Street is giving it credit for, and we expect Emergent to extend a number of its current contracts beyond current estimates. Emergent does not have the risk of commercial insurance reimbursement or payer pricing pressures on the majority of its portfolio.”

According to TipRanks.com, Folkes is a 3-star analyst with an average return of 4.0% and a 46.8% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Eagle Pharmaceuticals Inc, Collegium Pharmaceutical, and ANI Pharmaceuticals Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Emergent Biosolutions with a $69.50 average price target.

See today’s analyst top recommended stocks >>

Based on Emergent Biosolutions’ latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $20.95 million. In comparison, last year the company had a net profit of $33.94 million.

Based on the recent corporate insider activity of 52 insiders, corporate insider sentiment is negative on the stock. Most recently, in November 2018, Sue Bailey, a Director at EBS sold 17,717 shares for a total of $1,233,280.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures that address public health and national security threats. It includes Chemical, Biological, Radiological, Nuclear and Explosive or CBRNE threats; as well as emerging infectious diseases.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts